Nature Communications (Jun 2020)
Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia
- Xiao-Yan Zhao,
- Andreas Wilmen,
- Dongli Wang,
- Xinquan Wang,
- Maxine Bauzon,
- Ji-Yun Kim,
- Lars Linden,
- Liang Li,
- Ursula Egner,
- Tobias Marquardt,
- Dieter Moosmayer,
- Jan Tebbe,
- Julian Marius Glück,
- Philipp Ellinger,
- Kirk McLean,
- Shujun Yuan,
- Subramanian Yegneswaran,
- Xiaoqiao Jiang,
- Vince Evans,
- Jian-Ming Gu,
- Doug Schneider,
- Ying Zhu,
- Yifan Xu,
- Cornell Mallari,
- Ashley Hesslein,
- Yan Wang,
- Nicole Schmidt,
- Katrin Gutberlet,
- Christine Ruehl-Fehlert,
- Alexius Freyberger,
- Terry Hermiston,
- Chandra Patel,
- Derek Sim,
- Laurent O. Mosnier,
- Volker Laux
Affiliations
- Xiao-Yan Zhao
- US Innovation Center, Bayer
- Andreas Wilmen
- Biological Research, Bayer AG
- Dongli Wang
- Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University
- Xinquan Wang
- Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University
- Maxine Bauzon
- US Innovation Center, Bayer
- Ji-Yun Kim
- US Innovation Center, Bayer
- Lars Linden
- Biological Research, Bayer AG
- Liang Li
- Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University
- Ursula Egner
- Structural Biology, Bayer AG
- Tobias Marquardt
- Structural Biology, Bayer AG
- Dieter Moosmayer
- Structural Biology, Bayer AG
- Jan Tebbe
- Biological Research, Bayer AG
- Julian Marius Glück
- Biological Research, Bayer AG
- Philipp Ellinger
- Biological Research, Bayer AG
- Kirk McLean
- US Innovation Center, Bayer
- Shujun Yuan
- US Innovation Center, Bayer
- Subramanian Yegneswaran
- US Innovation Center, Bayer
- Xiaoqiao Jiang
- US Innovation Center, Bayer
- Vince Evans
- US Innovation Center, Bayer
- Jian-Ming Gu
- US Innovation Center, Bayer
- Doug Schneider
- US Innovation Center, Bayer
- Ying Zhu
- US Innovation Center, Bayer
- Yifan Xu
- US Innovation Center, Bayer
- Cornell Mallari
- US Innovation Center, Bayer
- Ashley Hesslein
- Biological Development, Bayer
- Yan Wang
- US Innovation Center, Bayer
- Nicole Schmidt
- US Innovation Center, Bayer
- Katrin Gutberlet
- Pathology/Toxicology, Bayer AG
- Christine Ruehl-Fehlert
- Pathology/Toxicology, Bayer AG
- Alexius Freyberger
- Pathology/Toxicology, Bayer AG
- Terry Hermiston
- US Innovation Center, Bayer
- Chandra Patel
- US Innovation Center, Bayer
- Derek Sim
- US Innovation Center, Bayer
- Laurent O. Mosnier
- The Scripps Research Institute
- Volker Laux
- TRG-Cardiology/Hematology, Bayer AG
- DOI
- https://doi.org/10.1038/s41467-020-16720-9
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Activated protein C (APC) is a plasma serine protease with antithrombotic and cytoprotective functions. Here, the authors develop a monoclonal antibody that specifically inhibits APC’s anticoagulant function without compromising its cytoprotective function, and shows efficacy in animal models.
